{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-086136","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2026-08-06T20:07:36+00:00","discovered_at":"2026-08-06T20:09:00.255357+00:00","generated_at":"2026-08-06T20:09:58.097435+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"60 Degrees Pharmaceuticals shareholders approve reverse stock split, equity plan amendment, and management success fee","bullets":["Reverse stock split approved at ratio of 1:5 to 1:10, as determined by board.","Equity plan amended to increase shares available by 800,000.","Success fee approved: 5% of deal proceeds between $40M-$100M, 6% above $100M, for change of control or sale of Arakoda.","Five directors elected: Geoffrey Dow, Eric Francois, Cheryl Xu, Stephen Toovey, Paul Field.","Ratification of RBSM LLP as independent auditor for FY 2026 approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-086136","json":"https://secwatch.observer/filing/0001213900-26-086136.json","markdown":"https://secwatch.observer/filing/0001213900-26-086136.md","text":"https://secwatch.observer/filing/0001213900-26-086136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026086136/0001213900-26-086136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026086136/ea0300977-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:09:58.097435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}